Axon Enterprise - AXON Stock Forecast, Price & News

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXON shares.
View AXON analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12-month price objectives for Axon Enterprise's stock. Their AXON share price forecasts range from $155.00 to $263.00. On average, they anticipate the company's stock price to reach $221.64 in the next year. This suggests a possible upside of 2.3% from the stock's current price.
View analysts price targets for AXON or view top-rated stocks among Wall Street analysts.

Axon Enterprise's stock was trading at $165.93 on January 1st, 2023. Since then, AXON shares have increased by 30.5% and is now trading at $216.58.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AXON earnings forecast.

Axon Enterprise, Inc. (NASDAQ:AXON) released its quarterly earnings data on Monday, November, 15th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.91. The biotechnology company earned $231.99 million during the quarter, compared to analysts' expectations of $201.11 million. Axon Enterprise had a trailing twelve-month return on equity of 12.70% and a net margin of 12.36%. The business's revenue for the quarter was up 39.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.01) earnings per share.

ETFs with the largest weight of Axon Enterprise (NASDAQ:AXON) stock in their portfolio include AdvisorShares Drone Technology ETF (UAV), Motley Fool Mid-Cap Growth ETF (TMFM), Motley Fool Global Opportunities ETF (TMFG), iShares U.S. Aerospace & Defense ETF (ITA), BlackRock Future Innovators ETF (BFTR), SPDR S&P Aerospace & Defense ETF (XAR), Invesco Aerospace & Defense ETF (PPA) and Innovator Loup Frontier Tech ETF (LOUP).

Axon Enterprise issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.43B-, compared to the consensus revenue estimate of $1.38 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Axon Enterprise's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.49%), William Blair Investment Management LLC (2.40%), Morgan Stanley (1.98%), Franklin Resources Inc. (1.61%), Alliancebernstein L.P. (1.42%) and Conestoga Capital Advisors LLC (1.38%). Insiders that own company stock include Adriane M Brown, Caitlin Elizabeth Kalinowski, Hadi Partovi, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Mark W Kroll, Matthew R Mcbrady, Matthew R Mcbrady, Michael Garnreiter and Patrick W Smith.
View institutional ownership trends.

Shares of AXON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXON stock can currently be purchased for approximately $216.58.

Axon Enterprise (NASDAQ:AXON) has a market capitalization of $15.78 billion and generates $1.19 billion in revenue each year. The biotechnology company earns $147.14 million in net income (profit) each year or $2.04 on an earnings per share basis.

The company employs 3,734 workers across the globe.

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The official website for the company is www.axovant.com. The biotechnology company can be reached via phone at (480) 991-0797, via email at ir@axon.com, or via fax at 480-991-0791.